Why the study?
Does the addition of an antacid buffer to tetravalent rhesus rotavirus vaccine improve its immunogenicity and does it interfere with the immune response to concurrently administered oral polio vaccine in infants?
Does the addition of an antacid buffer to tetravalent rhesus rotavirus vaccine improve its immunogenicity and does it interfere with the immune response to concurrently administered oral polio vaccine in infants?
Administration of tetravalent rhesus rotavirus vaccine with an antacid buffer significantly improves its immunogenicity without interfering with the immune response to concurrently administered oral polio vaccine.
Buffer addition to RRV-TV should be routine to maximize infant immunogenicity; confirms safe concurrent OPV use.
Between January and November 1989, we studied 174 infants aged 6 to 16 weeks in a randomized clinical trial to (1) determine the immunogenicity of a single dose of tetravalent rhesus rotavirus vaccine (RRV-TV) when administered with three different buffer regimens: no antacid buffer and small-volume (2.5-mL) and large-volume (30-mL) antacid buffer; and (2) examine the potential interference of RRV-TV on the immune response to oral polio vaccine. Immunogenicity of RRV-TV, measured as a fourfold rise in antibody titers to rotavirus, was similar in the groups receiving small- and large-dose buffer (45% and 49%, respectively) and significantly less in the group that received RRV-TV alone (23%). Administration of RRV-TV with oral polio vaccine did not significantly interfere with the neutralization response of oral polio vaccine poliovirus serotypes 1, 2, or 3, and overall, 29%, 87%, and 24% of the infants had a fourfold rise in titer to each serotype, respectively.
No takes yet. Share an insight, caveat, or question.
Donna J. Ing (1991) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: